Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies

Science

Volumn 318, Issue 5848, 2007, Pages 287-290

  Stommel, Jayne M ^a   Kimmelman, Alec C ^a   Ying, Haoqiang ^a   Nabioullin, Roustem ^b   Ponugoti, Aditya H ^b   Wiedemeyer, Ruprecht ^a   Stegh, Alexander H ^a   Bradner, James E ^a   Ligon, Keith L ^a,c   Brennan, Cameron ^d,e   Chin, Lynda ^a,b,c   DePinho, Ronald A ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERLOTINIB; IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR; SCATTER FACTOR RECEPTOR; SU 11274; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG;

BRAIN; ENZYME; GROWTH; HYPOTHESIS TESTING; RNA; TUMOR;

ARTICLE; CELL SURVIVAL; DOWNSTREAM PROCESSING; DRUG EFFICACY; ENZYME ACTIVATION; GLIOMA CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RNA INTERFERENCE; TUMOR CELL; TUMOR CELL LINE; TUMOR GROWTH; TUMOR XENOGRAFT;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; ENZYME ACTIVATION; GLIOBLASTOMA; HUMANS; INDOLES; PHOSPHORYLATION; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS; PTEN PHOSPHOHYDROLASE; QUINAZOLINES; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, GROWTH FACTOR; SIGNAL TRANSDUCTION; SULFONAMIDES;

EID: 35348822482     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.1142946     Document Type: Article

References (22)

1. E. A. Maher et al., Genes Dev. 15, 1311 (2001).
2. L. C. Cantley, Science 296, 1655 (2002).
3. J. Li et al., Science 275, 1943 (1997).
4. H. Wang et al., Lab. Invest. 84, 941 (2004).
5. A. El-Obeid et al., Cancer Res. 57, 5598 (1997).
6. M. Nagane et al., Cancer Res. 56, 5079 (1996).
7. B. Wullich, H. P. Sattler, U. Fischer, E. Meese, Anticancer Res. 14, 577 (1994).
8. P. Y. Wen et al., Clin. Cancer Res. 12, 4899 (2006).
9. J. N. Rich et al., J. Clin. Oncol. 22, 133 (2004).
10. I. K. Mellinghoff et al., N. Engl. J. Med. 353, 2012 (2005).
11. Materials and methods and supplementary figures are available as supporting material on Science Online.
12. J. C. Obenauer, L. C. Cantley, M. B. Yaffe, Nucleic Acids Res. 31, 3635 (2003).
13. N. E. Hynes, H. A. Lane, Nat. Rev. Cancer 5, 341 (2005).
14. H. Gu, B. G. Neel, Trends Cell Biol. 13, 122 (2003).
15. K. M. Weidner et al., Nature 384, 173 (1996).
16. R. Nishikawa et al., Proc. Natl. Acad. Sci. U.S.A. 91, 7727 (1994).
17. M. A. Fabian et al., Nat. Biotechnol. 23, 329 (2005).
18. H. Varmus, Science 312, 1162 (2006).
19. Y. Sonoda et al., Cancer Res. 61, 4956 (2001).
20. K. Sugawara et al., Lab. Invest. 82, 345 (2002).
21. K. L. Ligon et al., J. Neuropathol. Exp. Neurol. 63, 499 (2004).
22. We thank W. Cavenee and F. Furnari for glioma cell lines; R. Pieper for the E6/E7/hTERT normal human fibroblasts; A. Chan for the myr-Akt construct; members of the DePinho and Chin laboratories, J. Engelman, and L. C. Cantley for helpful discussions; and Y.-H. Xiao, B. Feng, and J. Zhang for bioinformatic help. J.M.S. is funded by the American Brain Tumor Association and a Ruth L. Kirschstein National Research Service Award. H.Y. is funded by the American Brain Tumor Association. A.C.K. is a recipient of the Leonard B. Holman Research Pathway Fellowship. R.W. is supported by a Mildred Scheel Fellowship (Deutsche Krebshilfe). Grant support comes from The Claudia Adam Barr Foundation (A.H.S.), the Goldhirsh Foundation (L.C.), and NIH grants RO1CA99041 (L.C.) and 5P01CA95616 (R.A.D., L.C., C.B., and K.L.L.). R.A.D. is an American Cancer Society Research Professor and an Ellison Medical Foundation Scholar and is supported by the Robert A. and Renee E. Belfer Foundation Institute for Innovative Cancer Science. This work was conducted solely at the Dana-Farber Cancer Institute and has no industrial connection or influence. R.A.D. is a member of the Senior Advisory Board of Abbott Pharmaceuticals and is a cofounder, scientific advisor, and director of Aveo Pharmaceuticals. L.C. is a cofounder and scientific advisor of Aveo Pharmaceuticals.